Nurix Funding & Investors
Nurix, Inc. discovers and develops therapies. The Company develops small molecule inhibitors of ubiquitin ligases to treat a broad range of proliferative and degenerative diseases.
nurixtx.comTotal Amount Raised: $370,900,000
Nurix Funding Rounds
Post Ipo Equity
$40,000,000
Post Ipo Equity
$160,400,000
Private Equity
$120,000,000
Private Equity Investors
EcoR1 CapitalRedmile GroupBain Capital Life SciencesWellington ManagementThird Rock VenturesForesite CapitalThe Column GroupBoxer CapitalSeries C
$17,000,000
Series B
$25,100,000
Series B Investors
Third Rock VenturesThe Column GroupSeries Unknown
$5,300,000
Series Unknown Investors
Third Rock VenturesThe Column GroupSeed
$3,100,000
Seed Investors
Third Rock VenturesThe Column Group
Funding info provided by Diffbot.